|
Publikationen Dr. Edith Uetz-von Allmen
- Uetz-von Allmen E, Samson GPB, Purvanov V, Maeda T, Legler DF. 2021. CAL-1 as cellular model system to study CCR7-guided human dendritic cell migration. Front Immunol Sep 16;12:702453. doi: 10.3389/fimmu.2021.702453.
- Jørgensen AS, Larsen O, Uetz-von Allmen E, Lückmann M, Legler DF, Frimurer TM, Veldkamp CT, Hjortø GM, Rosenkilde MM. 2019. Biased Signaling of CCL21 and CCL19 Does Not Rely on N-Terminal Differences, but Markedly on the Chemokine Core Domains and Extracellular Loop 2 of CCR7. Front Immunol Sep 13;10:2156. doi: 10.3389/fimmu.2019.02156. eCollection 2019.
- Jakobs BD, Spannagel L, Purvanov V, Uetz-von Allmen E, Matti C, Legler DF. 2019. Engineering of Nanobodies Recognizing the Human Chemokine Receptor CCR7. Int J Mol Sci Int J Mol Sci. 2019 May 27;20(10). pii: E2597. doi: 10.3390/ijms20102597. Repository
- Uetz-von Allmen E, Rippl AV, Farhan H, Legler DF. 2018. A unique signal sequence of the chemokine receptor CCR7 promotes package into COPII vesicles for efficient receptor trafficking. J Leukoc Biol 104(2):375-389. Repository
- Legler DF, Matti C, Laufer JM, Jakobs BD, Purvanov V, Uetz-von Allmen E, Thelen M. 2017. Modulation of chemokine receptor function by cholesterol: new prospects for pharmacological intervention. Mol Pharmacol 91(4):331-338.
- Baschieri F, Uetz-von Allmen E, Legler DF, Farhan H. 2015. Loss of GM130 in breast cancer cells and its effects on cell migration, invasion and polarity. Cell Cycle 14:1139-1147.
- Legler DF, Uetz-von Allmen E, Hauser MA. 2014. CCR7: Roles in cancer cell dissemination, migration and metastasis formation. Int J Biochem Cell Biol 54:78-82.
- Legler DF, Bruckner M, Uetz-von Allmen E, Krause P. 2010. Prostaglandin E(2) at new glance: Novel insights in functional diversity offer therapeutic chances. Int J Biochem Cell Biol 42(2):198-201.
- Uetz-von Allmen E, Koch M, Fritz G, Legler DF. 2008. V domain of RAGE interacts with AGEs on prostate carcinoma cells.Prostate 68:748-758.
- Fischer S, Uetz-von Allmen E, Waeckerle-Men Y, Groettrup M, Merkle HP, Gander B. 2007. The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles. Biomaterials 28:994-1004.
- Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, von Moos R, Boehme C, Schmid HP, Ackermann D, Cerny T, Ludewig B, Groettrup M, Gillessen S. 2006. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 55(12):1524-33. Epub 2006 Apr 13
- Waeckerle-Men Y, Uetz-von Allmen E, Gander B, Scandella E, Schlosser E, Schmidtke G, Merkle HP, Groettrup M. 2006. Encapsulation of proteins and peptides into biodegradable poly(D,L-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine 24(11):1847-1857.
- Waeckerle-Men Y, Uetz-von Allmen E, von Moos R, Classon BJ, Scandella E, Schmid HP, Ludewig B, Groettrup M, Gillessen S. 2005. Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation. Prostate 64(4):323-331.
- Waeckerle-Men Y, Scandella E, Uetz-von Allmen E, Ludewig B, Gillessen S, Merkle HP, Gander B, Groettrup M. 2004. Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy. J Immunol Methods 287:109-124.
- Hari Y, von Allmen EC, Boss GM, Naiem A, Gittermann M, Nydegger UE. 1998. The complement activating capacity of maternal IgG antibodies to blood group A in paired mother/child serum samples. Vox Sang 74(2):95-100.
- Uetz-von Allmen E, Sturzenegger M, Rieben R, Rihs F, Frauenfelder A, Nydegger UE. 1998. Antiganglioside GM1 antibodies and their complement activating capacity in central and peripheral nervous system disorders and in controls. Europ Neurol 39(2):103-110.
- Rieben R, von Allmen E, Korchagina EY, Nydegger UE, Neethling FA, Kujundzic M, Koren E, Bovin NV, Cooper DKC. 1995. Detection, immunoabsorption, and inhibition of cytotoxic activity of anti-alpha Gal antibodies using newly developed substances with synthetic Gal alpha1-3 Gal disaccharide epitopes. Xenotransplantation 2:98-106.
- Rieben R, Korchagina EY, von Allmen E, Kremer Hovinga J, Lämmle B, Jungi TW, Bovin NV, Nydegger UE. 1995. In vitro evaluation of the efficacy and biocompatibility of new, synthetic ABO immunoabsorbents. Transplantation 60(5):425-430.
- von Allmen E, Rieben R, Nydegger UE. 1994. Development of a C1q-ABO-ELISA to measure C1q binding by human anti-A alloantibodies. J Immunol Methods 171:85-92.
